Regencell Bioscience Holdings (Regencell Bioscience Holdings) Long-Term Capital Lease Obligation

: $0.03 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Regencell Bioscience Holdings's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.03 Mil.

Regencell Bioscience Holdings's quarterly Long-Term Capital Lease Obligation declined from Jun. 2022 ($0.36 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($0.03 Mil).

Regencell Bioscience Holdings's annual Long-Term Capital Lease Obligation increased from Jun. 2021 ($0.00 Mil) to Jun. 2022 ($0.36 Mil) but then declined from Jun. 2022 ($0.36 Mil) to Jun. 2023 ($0.03 Mil).

Regencell Bioscience Holdings Long-Term Capital Lease Obligation Historical Data

The historical data trend for Regencell Bioscience Holdings's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Long-Term Capital Lease Obligation

0.36

0.03

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial				-	-	0.36	-	0.03

Regencell Bioscience Holdings (NAS:RGC) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Regencell Bioscience Holdings Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.